Johnson & Johnson (JNJ) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Pharmaceuticals) last closed at $256.03. The rating moved from Overbought to Oversold on September 30, 2026.

• Public ratingOversold (as of October 3, 2026)
• Last close$256.03
• Last changeMoved from Overbought to Oversold on September 30, 2026
• SectorHealthcare
• IndustryPharmaceuticals

See all oversold Healthcare stocks →

AI analysis

Johnson & Johnson (JNJ) combines a diversified, defensive franchise mix with steady free cash flow and a strong balance sheet, supporting dividends and strategic flexibility. Near-term catalysts include continued recovery in elective procedures for devices, upside from key pharmaceutical franchises and potential pipeline or bolt-on M&A. Headwinds stem from intensified payer scrutiny (Medicare negotiation), competitive dynamics in metabolic therapies, and episodic regulatory or litigation risks. Given current market risk‑off tone, the company should show relative resilience, though outcomes will depend on drug‑pricing developments and execution on clinical programs.

Key factors

• Diversified business mix across pharmaceuticals, medical devices and diagnostics provides revenue stability and reduces single‑asset exposure.
• Leading branded franchises and mid-to-late stage pipeline assets support above-market margins and future revenue upside.
• Strong free cash flow generation and a conservative balance sheet enable sustained dividend, share repurchases, and M&A optionality.
• Defensive market positioning benefits during risk‑off periods; flows into healthcare may support near-term relative outperformance.
• Operational scale and global commercial footprint provide resilience against regional demand shocks and pricing pressures.

Risks

• Policy and payer pressure from Medicare drug‑price negotiation (IRA) that could compress pricing and volumes for high-cost drugs.
• Competitive disruption in metabolic/weight-loss therapies (GLP-1 and amylin combos) that may erode addressable market or pricing for related indications.
• Weakness in device/consumer capital markets and a cooling IPO window, which could reduce exit valuations and slow device-sector investment.
• Ongoing litigation, regulatory setbacks, or unexpected trial readouts that could create episodic volatility or cash outflows.
• Supply-chain constraints, inflationary input costs, and FX exposure that can compress margins if not fully offset by pricing or productivity.

Latest MarketMoodz coverage

• Cramer’s 5 Stocks to Buy During the Market Rotation2026-07-06
• Chip Stocks Rally as Goldman’s M&A Streak Spurs Rotation2026-06-29
• Salesforce reportedly to buy Fin for $3.6B to beef up Agentforce AI2026-06-15
• Goldman Sees Nvidia Upside; What Tech Investors Should Do2026-06-13
• Oracle Earnings Loom: Options Price a 12% Move2026-06-09

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.